Effects of herbal supplements on the bioactivation of chemotherapeutic agents

Gorman, Gregory S.; Coward, Lori; Darby, Adrienne; Rasberry, Bethany

doi:10.1111/jphp.12055

Cited by 18 publications

(12 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical studies found ginger as effective and safe to prevent pregnancy-associated nausea and vomiting ( Borrelli et al, 2005 ; Ding et al, 2013 ). In human liver microsomes, the hydroethanolic extract inhibited CYP2C19 and CYP2D6 ( Kim et al, 2012 ; Gorman et al, 2013 ).…”

Section: Resultsmentioning

confidence: 99%

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

et al. 2020

View full text Add to dashboard Cite

Background: Current recommendations for the self-management of SARS-Cov-2 disease (COVID-19) include self-isolation, rest, hydration, and the use of NSAID in case of high fever only. It is expected that many patients will add other symptomatic/adjuvant treatments, such as herbal medicines. Aims: To provide a benefits/risks assessment of selected herbal medicines traditionally indicated for "respiratory diseases" within the current frame of the COVID-19 pandemic as an adjuvant treatment. Method: The plant selection was primarily based on species listed by the WHO and EMA, but some other herbal remedies were considered due to their widespread use in respiratory conditions. Preclinical and clinical data on their efficacy and safety were collected from authoritative sources. The target population were adults with early and mild flu symptoms without underlying conditions. These were evaluated according to a modified PrOACT-URL method with paracetamol, ibuprofen, and codeine as reference drugs. The benefits/risks balance of the treatments was classified as positive, promising, negative, and unknown. Results: A total of 39 herbal medicines were identified as very likely to appeal to the COVID-19 patient. According to our method, the benefits/risks assessment of the herbal medicines was found to be positive in 5 cases (Althaea officinalis, Commiphora molmol, Glycyrrhiza glabra, Hedera helix, and Sambucus nigra), promising in 12 cases (Allium sativum, Andrographis paniculata, Echinacea angustifolia, Echinacea purpurea, Eucalyptus globulus essential oil, Justicia pectoralis, Magnolia officinalis, Mikania glomerata, Pelargonium sidoides, Pimpinella anisum, Salix sp, Zingiber officinale), and unknown for the rest. On the same grounds, only ibuprofen resulted promising, but we could not find compelling evidence to endorse the use of paracetamol and/or codeine. Conclusions: Our work suggests that several herbal medicines have safety margins superior to those of reference drugs and enough levels of evidence to start a clinical

show abstract

Section: Resultsmentioning

confidence: 99%

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…SJW has been described through several studies as an HMP product that can lead in clinically significant PK and PD interactions [54,55,56]. Especially for SJW, the underlying pharmacological mechanisms of the PK and PD interactions have been described in detail [57,58]. SJW contain different groups of compounds such as hypericin, hyperforin, and flavonoids.…”

Section: Methodsmentioning

confidence: 99%

PharmActa: Empowering Patients to Avoid Clinical Significant Drug–Herb Interactions

et al. 2019

View full text Add to dashboard Cite

Herbal medicinal products (HMPs) are the subject of increasing interest regarding their benefits for health. However, a serious concern is the potential appearance of clinically significant drug–herb interactions in patients. This work provides an overview of drug–herb interactions and an evaluation of their clinical significance. We discuss how personalized health services and mobile health applications can utilize tools that provide essential information to patients to avoid drug–HMP interactions. There is a specific mention to PharmActa, a dedicated mobile app for personalized pharmaceutical care with information regarding drug–HMPs interactions. Several studies over the years have shown that for some HMPs, the potential to present clinically significant interactions is evident, especially for many of the top selling HMPs. Towards that, PharmActa presents how we can improve the way that information regarding potential drug–herb interactions can be disseminated to the public. The utilization of technologies focusing on medical information and context awareness introduce a new era in healthcare. The exploitation of eHealth tools and pervasive mobile monitoring technologies in the case of HMPs will allow the citizens to be informed and avoid potential drug–HMPs interactions enhancing the effectiveness and ensuring safety for HMPs.

show abstract

“…Compared to St John's wort and ginger root extract, black cohosh was the strongest inhibitor for both CYP and carboxylesterase-mediated biotransformation of tamoxifen and irinotecan, respectively, to their active metabolites (Gorman et al, 2013). The clinical significance of these results needs to be evaluated in a comprehensive clinical trial.…”

Section: Adverse Effects and Safetymentioning

confidence: 99%

Chemical and biological studies of Cimicifugeae pharmaceutical resources

Hao¹,

Gu²,

Xiao³

2015

Medicinal Plants

View full text Add to dashboard Cite

Effects of herbal supplements on the bioactivation of chemotherapeutic agents

Abstract: Commercially available supplements are widely used by patients and their potential impact on the efficacy of the chemotherapy is often unknown. The clinical significance of these results needs to be evaluated in a comprehensive clinical trial.

Cited by 18 publications

References 42 publications

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

PharmActa: Empowering Patients to Avoid Clinical Significant Drug–Herb Interactions

Chemical and biological studies of Cimicifugeae pharmaceutical resources

Contact Info

Product

Resources

About